Department of Research and Development, Amsterdam Molecular Therapeutics, Amsterdam, The Netherlands.
Gene Ther. 2011 Sep;18(9):929-35. doi: 10.1038/gt.2011.41. Epub 2011 Apr 7.
RNA interference (RNAi) has been successfully employed for specific inhibition of gene expression; however, safety and delivery of RNAi remain critical issues. We investigated the combinatorial use of RNAi and U1 interference (U1i). U1i is a gene-silencing technique that acts on the pre-mRNA by preventing polyadenylation. RNAi and U1i have distinct mechanisms of action in different cellular compartments and their combined effect allows usage of minimal doses, thereby avoiding toxicity while retaining high target inhibition. As a proof of concept, we investigated knockdown of the firefly luciferase reporter gene by combinatorial use of RNAi and U1i, and evaluated their inhibitory potential both in vitro and in vivo. Co-transfection of RNAi and U1i constructs showed additive reduction of luciferase expression up to 95% in vitro. We attained similar knockdown when RNAi and U1i constructs were hydrodynamically transfected into murine liver, demonstrating for the first time successful in vivo application of U1i. Moreover, we demonstrated long-term gene silencing by AAV-mediated transduction of murine muscle with RNAi/U1i constructs targeting firefly luciferase. In conclusion, these results provide a proof of principle for the combinatorial use of RNAi and U1i to enhance target gene knockdown in vivo.
RNA 干扰 (RNAi) 已成功用于特定的基因表达抑制;然而,RNAi 的安全性和递送仍然是关键问题。我们研究了 RNAi 和 U1 干扰 (U1i) 的联合使用。U1i 是一种基因沉默技术,通过阻止多聚腺苷酸化作用于前体 mRNA。RNAi 和 U1i 在不同的细胞区室中具有不同的作用机制,它们的联合作用允许使用最小剂量,从而避免毒性,同时保持高靶抑制。作为概念验证,我们研究了 RNAi 和 U1i 的联合使用对萤火虫荧光素酶报告基因的敲低,并在体外和体内评估了它们的抑制潜力。RNAi 和 U1i 构建体的共转染显示体外荧光素酶表达的加性降低高达 95%。当 RNAi 和 U1i 构建体通过水力转染到鼠肝中时,我们获得了类似的敲低,这首次证明了 U1i 的体内成功应用。此外,我们通过 AAV 介导的转导,用靶向萤火虫荧光素酶的 RNAi/U1i 构建体对鼠肌肉进行长期基因沉默。总之,这些结果为 RNAi 和 U1i 的联合使用提供了体内增强靶基因敲低的原理证明。